Tumor uptake and elimination of 2′, 2′-difluoro-2′-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: Correlation with in vivo tumor response

Clinical Cancer Research

Volumn 7, Issue 10, 2001, Pages 3263-3268

  Blackstock, A William ^a   Swarts, Steve G ^a   Hess, Suzanne M ^a   Case, L Doug ^a   Lightfoot, Harry ^b   Tepper, Joel E ^b   Mukherji, Suresh K ^c   Mitchell, Beverly S ^c  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DEOXYCYTIDINE KINASE; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HT29; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG ELIMINATION; DRUG RESPONSE; DRUG UPTAKE; EXPRESSION VECTOR; FEMALE; GENE TRANSFER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUDE MOUSE; PRIORITY JOURNAL; RETROVIRUS; TUMOR XENOGRAFT;

ANIMALS; CELL DIVISION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTIDINE TRIPHOSPHATE; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; FEMALE; FLUORINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE TRANSFER TECHNIQUES; HT29 CELLS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034792689     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer
2. Preclinical in vivo activity of 2′, 2′-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer
3. Evaluation of the antitumor activity of gemcitabine (2′, 2′-difluoro-2′-deoxycytidine)
4. Schedule dependence of sensitivity to 2′, 2′-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours
5. Clinical and preclinical activity of 2′, 2′-difluorodeoxycytidine (gemcitabine)
6. Difluorodeoxycytidine (dFdC)-gemcitabine: A phase I study
7. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)
8. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
9. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity
10. 19F nuclear magnetic resonance spectroscopy
11. 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts
12. 19F nuclear magnetic resonance spectroscopy
13. Quantitation of deoxyribonucleoside 5′-triphosphates by a sequential boronate and anion-exchange high-pressure liquid chromatographic procedure
14. Gemcitabine: In vitro and in vivo evidence of its radiation sensitizing activity and studies using fluorine-19 magnetic resonance spectroscopy to determine the optimal dosing schedule - Preclinical observations relevant to gemcitabine clinical trials
15. Radiosensitization produced in vivo by once- vs. twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine)
16. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity
17. +-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells
18. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines
19. Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters
20. 3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line
21. Action of 2′, 2′-difluorodeoxycytidine on DNA synthesis
22. Cellular elimination of 2′, 2′-difluorodeoxycytidine 5′-triphosphate: A mechanism of self-potentiation
23. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism
24. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′, 2′-difluorodeoxycytidine
25. Radiosensitization of human tumor cells by gemcitabine in vitro